<DOC>
	<DOCNO>NCT02144740</DOCNO>
	<brief_summary>Part 2 study assess effect 2g NWT-03 ( egg-white protein hydrolysate ) systolic diastolic blood pressure flow-mediated dilation crossover design study healthy adult mild hypertension .</brief_summary>
	<brief_title>Effect NWT-03 Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Be able give write informed consent , Be 35 75 year age , Be generally good health determine investigator , Smokers nonsmoker eligible , Have stable body weight ( &lt; 5 % change ) past 3months , Have Body Mass Index ( BMI ) 25 35 kg/m2 , Be mild hypertensive ( Systolic Blood Pressure 140159 mmHg &amp; Diastolic Blood Pressure 8099 mmHg ) . Subjects exclude study meet criterion ; 1 . Are less 35 great 75 year age , 2 . Females pregnant , lactate wish become pregnant study . Female subject currently either : 1. nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal female surgically sterilize ( via document hysterectomy bilateral tubal ligation ) . ( For purpose study , postmenopausal define one year without menses ) , OR 2. child bear potential , subject eligible enter participate study lactate negative urine pregnancy test screen visit , visit 2 upon completion study visit 7 . The subject must also agree one follow method contraception : Complete abstinence intercourse two week prior administration study drug , throughout clinical trial , completion followup procedure two week follow discontinuation study medication case subject discontinues study prematurely . ( Subjects utilize method must agree use alternate method contraception become sexually active query whether abstinent precede 2 week present clinic Final Visit . ) , male sexual partner surgically sterilize prior Screen Visit male sexual partner subject , sexual partner ( ) is/are exclusively female , Oral contraceptive ( either combine progestogen ) doublebarrier method contraception consist spermicide either condom diaphragm . ( Women childbearing potential use oral contraceptive combination doublebarrier method contraception require continue use form contraception 1 week follow discontinuation study medication ) . Use doublebarrier contraception , specifically , spermicide plus mechanical barrier ( e.g . male condom , female diaphragm ) . The subject must use method least 1 week follow end study , Use intrauterine device ( IUD ) publish data show high expected failure rate le 1 % per year . The subject must device insert least 2 week prior first Screen Visit , throughout study , 2 week follow end study . 3 . Are hypersensitive component test product , 4 . Have significant acute chronic coexist illness cardiovascular disease , Chronic kidney disease ( CKD ) , gastrointestinal disorder , endocrinological disorder , immunological disorder , metabolic disease condition contraindicates , investigator judgement , entry study , 5 . Having condition take medication investigator believe would interfere objective study , pose safety risk confound interpretation study result ; include diuretic , blood pressure medication medication interfere reninangiotensinaldosterone system ( RAAS ) , ACEinhibitors , angiotensin receptor blocker , direct renin inhibitor aldosterone receptor inhibitor , 6 . Are take nonsteroidal antiinflammatory drug ( NSAIDs ) within 2 week baseline visit duration trial , 7 . Suffer diabetes mellitus , either type I type II , 8 . Consume recommend alcohol guideline i.e . &gt; 21 alcohol units/week male &gt; 14 units/week female , 9 . History illicit drug use , 10 . Use nasal decongestant overthe counter herbal preparation within 2 week baseline visit duration trial , 11 . Heavy intake coffee ( i.e . 4 cup daily ) within 2 week baseline visit duration trial , 12 . Individuals , opinion investigator , consider poor attendee unlikely reason able comply trial , 13 . Subjects may receive treatment involve experimental drug , 14 . If subject recent experimental trial , must complete less 60 day prior study . An exception make subject participated part 1 study , 15 . Have malignant disease concomitant endstage organ disease .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Flow-mediated dilation</keyword>
</DOC>